Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Keymed Biosciences's Enterprise Value is €2,028.7 Mil.
Keymed Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-12.2 Mil. Therefore, Keymed Biosciences's EV-to-OCF for today is -166.20.
The historical rank and industry rank for Keymed Biosciences's EV-to-OCF or its related term are showing as below:
FRA:64Z'
s EV-to-OCF Range Over the Past 10 Years
Min: -37.37 Med: -18.02 Max: 4.64
Current: -23.65
During the past 7 years, the highest EV-to-OCF of Keymed Biosciences was 4.64. The lowest was -37.37. And the median was -18.02.
FRA:64Z's EV-to-OCF is ranked better than 96.94% of 1406
companies
in the Biotechnology industry
Industry Median: -3.37
vs FRA:64Z: -23.65
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Keymed Biosciences's PE Ratio (TTM) for today is calculated as:
Keymed Biosciences's share price for today is €7.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Keymed Biosciences EV-to-OCF Related Terms
Keymed Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Keymed Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Keymed Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's EV-to-OCF falls into.
Keymed Biosciences's current Enterprise Value is €2,028.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Keymed Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-12.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences (FRA:64Z) has a EV-to-OCF of -166.20 as of Sep. 20, 2026. According to the industry distribution chart, Keymed Biosciences ranks #43 out of 1406 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Keymed Biosciences' EV-to-OCF too high?
Keymed Biosciences' current EV-to-OCF is -166.20. Based on the distribution chart, Keymed Biosciences ranks #43 out of 1406 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Keymed Biosciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #43 out of 1406 companies for EV-to-OCF. This places Keymed Biosciences in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Keymed Biosciences's current EV-to-OCF is -166.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Keymed Biosciences (FRA:64Z) has a current EV-to-OCF of -166.20. The stock's GF Value™ is €16.65, compared to a current price of €7.90 — trading 52.6% below its estimated fair value. The current EV-to-OCF is -166.20. Keymed Biosciences' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current EV-to-OCF is -166.20 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of €7.90 is trading 52.6% below its estimated GF Value™ of €16.65.
Key valuation signals for FRA:64Z:
EV-to-OCF: -166.20
GF Value™: €16.65 vs. price of €7.90 (52.6% below fair value)
No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
49GF Score
Get the complete analysis for FRA:64Z
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:64Z has been successfully added to your 
